首页> 美国卫生研究院文献>other >Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients
【2h】

Urinary uromodulin independently predicts end-stage renal disease and rapid kidney function decline in a cohort of chronic kidney disease patients

机译:一组慢性肾脏疾病患者的尿中尿调节蛋白可独立预测终末期肾脏疾病和肾脏功能快速下降

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Data on risk factors predicting rapid progression to end-stage renal disease (ESRD) or short-term kidney function decline (i.e., within 1 year) in chronic kidney disease (CKD) are rare but urgently needed to plan treatment. This study describes the association and predictive value of urinary uromodulin (uUMOD) for rapid progression of CKD.We assessed uUMOD, demographic/treatment parameters, estimated glomerular filtration rate (eGFR), and proteinuria in 230 CKD patients stage I-V. ESRD and 25% decline of eGFR was documented at the end of follow-up period and used as a composite endpoint. Association between logarithmic uUMOD and eGFR/proteinuria was calculated using linear regression analysis, adjusting for age, gender, and body mass index. We performed multivariable Cox proportional hazard regression analysis to evaluate the association of uUMOD with the composite endpoint. Therefore, patients were categorized into quartiles. The predictive value of uUMOD for the above outcomes was assessed using receiver-operating characteristic (ROC) curve analysis.Follow-up was 57.3 ± 18.7 weeks, baseline age was 60 (18;92) years, and eGFR was 38 (6;156) mL/min/1.73 m2. Forty-seven (20.4%) patients reached the composite endpoint. uUMOD concentrations were directly associated with eGFR and inversely associated with proteinuria (β = 0.554 and β = -0.429, P < .001). In multivariable Cox regression analysis, the first 2 quartiles of uUMOD concentrations had a hazard ratio (HR) of 3.589 [95% confidence interval (95% CI) 1.002–12.992] and 5.409 (95% CI 1.444–20.269), respectively, in comparison to patients of the highest quartile (≥11.45 μg/mL) for the composite endpoint. In ROC-analysis, uUMOD predicted the composite endpoint with good sensitivity (74.6%) and specificity (76.6%) at an optimal cut-off at 3.5 μg/mL and area under the curve of 0.786 (95% CI 0.712–0.860, P < .001).uUMOD was independently associated with ESRD/rapid loss of eGFR. It might serve as a robust predictor of rapid kidney function decline and help to better schedule arrangements for future treatment.
机译:预测慢性肾脏病(CKD)中快速发展为终末期肾病(ESRD)或短期肾功能下降(即1年内)的危险因素的数据很少,但迫切需要制定治疗计划。这项研究描述了尿尿调节素(uUMOD)对CKD快速进展的关联和预测价值。我们评估了230例CKD I-V期患者的uUMOD,人口统计学/治疗参数,估计的肾小球滤过率(eGFR)和蛋白尿。在随访期结束时记录了ESRD和eGFR下降25%,并将其用作复合终点。使用线性回归分析计算对数uUMOD与eGFR /蛋白尿之间的关联,并调整年龄,性别和体重指数。我们进行了多变量Cox比例风险回归分析,以评估uUMOD与复合终点的关联。因此,将患者分类为四分位数。 uUMOD对上述结果的预测价值通过接受者操作特征(ROC)曲线分析进行评估。随访时间为57.3±18.7周,基线年龄为60(18; 92)岁,eGFR为38(6; 156) )mL / min / 1.73 m 2 。 47名(20.4%)患者达到了复合终点。 uUMOD浓度与eGFR直接相关,与蛋白尿呈负相关(β= 0.554和β= 0.4-0.229,P <0.001)。在多变量Cox回归分析中,uUMOD浓度的前两个四分位数的危险比(HR)分别为3.589 [95%置信区间(95%CI)1.002-12.992]和5.409(95%CI 1.444-20.269)。与复合终点最高四分位数(≥11.45μg/ mL)的患者进行比较。在ROC分析中,uUMOD预测复合终点具有最佳灵敏度(74.6%)和特异性(76.6%),最佳临界值为3.5μg/ mL,曲线下面积为0.786(95%CI 0.712–0.860,P <.001).uUMOD与ESRD / eGFR的快速丧失独立相关。它可以作为肾功能快速下降的有力预测指标,有助于更好地安排日后治疗的安排。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号